drugset
Drugs / PATH-wSP
last change Sep 2025 re-read 2 minutes ago

PATH-wSP

also known as wSp vaccine · SPWCV

Vaccine

Developed for
otitis media · idiopathic severe pneumococcemia · pneumonia · streptococcal pneumonia
Investigated by
PATH · Serum Life Science Europe GmbH · Alira Health · National Institute of Allergy and Infectious Diseases (NIAID) · Rochester General Hospital · Serum Institute of India Pvt. Ltd.

Trials 4 · a red edge is where a trial was stopped

today NCT07216430 · Ph 2 NCT07059182 · Ph 1 NCT02543892 · Ph 1/2 NCT02097472 · Ph 1/2
201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT07059182 Jun → Aug 2025 idiopathic severe pneumococcemia, otitis media Serum Life Science Europe GmbH Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT02543892 Aug 2016 → Jan 2018 pneumonia PATH Completed No outcome recorded
Phase 1/2 NCT02097472 Apr 2014 → Dec 2015 streptococcal pneumonia PATH Completed No outcome recorded
Phase 21 trial
Phase 2 NCT07216430 Sep 2025 → Jun 2028 expected otitis media Serum Life Science Europe GmbH Recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as PATH wSP “A single-vial formulation of PATH wSP, an adsorbed suspension of SPWCV and Alum, has now been manufactured by PT Bio Farma, Indonesia.” NCT02543892 ↗
2

NCT02097472 ↗

NCT02543892 ↗
Known as SPWCV “S. pneumoniae whole cell vaccine (SPWCV) is a vaccine candidate made from whole, unencapsulated pneumococcal cells.” NCT02097472 ↗
Known as wSp vaccine “Single intramuscular injection of 1 mg protein/0.5 mL wSp vaccine” NCT07059182 ↗
1

NCT07216430 ↗
Modality Vaccine “S. pneumoniae whole cell vaccine (SPWCV)” NCT02097472 ↗
Route Intramuscular “administered intramuscularly” NCT02097472 ↗